PREM14A filed Aug 10, 2026 at 16:34 ET
Bio-Techne (TECH) filed a preliminary proxy statement (PREM14A) for a special shareholder meeting to vote on its acquisition by Merck KGaA (Parent) for $73.00 per share in cash, a 24% premium over the $58.88 closing price on June 24, 2026. The all-cash deal values Bio-Techne at an implied total enterprise value of approximately $11.3 billion. The Board unanimously recommends approval, and Goldman Sachs rendered a fairness opinion. The merger is expected to close by late 2026 or early 2027, subject to shareholder and regulatory approvals, with no financing condition for Parent.